TLR3 and Recurrent upper respiratory tract infections: A phase 2 trial was conducted for common cold using oral homeopathic antibody as a tablet formulation against the TLR3 FYW peptide (TAO1); it showed efficacy against moderate-to-severe upper respiratory tract infection (NCT01651715) [30].